Scarica l'app Stockscreener
1.21
3.23%
-0.03
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Cognition Therapeutics (CGTX) to Release Earnings on Wednesday - MarketBeat
Cognition Therapeutics | DEF 14A: Definitive information statements - Moomoo
Cognition Therapeutics | DEFA14A: Others - Moomoo
Cognition Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] COGNITION THERAPEUTICS INC SEC Filing - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) outlines 2026 virtual meeting, director elections and EY ratification - Stock Titan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cognition Therapeutics, Inc. (CGTX) - Minichart
Top Brass Makes Bold Move With Fresh Insider Buying Spree at Cognition Therapeutics - TipRanks
Insider Buying: John Doyle Acquires 10,000 Shares of Cognition T - GuruFocus
John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock - MarketBeat
Cognition therapeutics CMO buys $11,100 in common stock - Investing.com
Cognition therapeutics CFO John Doyle buys $11,299 in stock - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares - Investing.com
Cognition therapeutics CEO Lisa Ricciardi buys $10,092 in shares By Investing.com - Investing.com India
Cognition therapeutics CFO John Doyle buys $11,299 in stock By Investing.com - Investing.com South Africa
Cognition therapeutics CMO buys $11,100 in common stock By Investing.com - Investing.com Canada
Cognition Therapeutics (CGTX) CFO adds 10,000 shares in open-market buy - Stock Titan
Cognition Therapeutics (CGTX) CEO buys 9,175 open-market shares - Stock Titan
Insider buy: Cognition Therapeutics (CGTX) CMO adds 10,000 shares - Stock Titan
Cognition Therapeutics (CGTX.US) achieved positive results in the CT1812 trial for Alzheimer's disease medication. - 富途牛牛
CGTX: Phase III trials for zervimesine in DLB psychosis and Alzheimer's are advancing with strong safety and efficacy data - TradingView
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans - Yahoo Finance
Update Report: Can Cognition Therapeutics Inc disrupt its industryQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Insider Trends: Whats the fair value of Cognition Therapeutics Inc stockSell Signal & Real-Time Market Sentiment Reports - baoquankhu1.vn
Insider Sell: Can Cognition Therapeutics Inc disrupt its industryPortfolio Gains Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Big Picture: Whats the fair value of Cognition Therapeutics Inc stockQuarterly Trade Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Lewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034– DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Barchart.com
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - Bitget
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
CEO to give Alzheimer's, Lewy body drug update on April 13 - Stock Titan
Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Will Cognition (CGTX) Stock Hit Record Highs | Price at $0.89, Up 1.96%Institutional Buying - Cổng thông tin điện tử Tỉnh Sơn La
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
CGTX Stock Analysis: Cognition Therapeutics Inc. posts 17.37 pct gain near 1 dollar resistance - Cổng thông tin điện tử Tỉnh Sơn La
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - Investing.com
Cognition Therapeutics CEO Issues Letter to Shareholders - 富途牛牛
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - Minichart
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛
Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):